A lot of our body’s functions depend on when we are defecating and how well our bowel movements are taking place. People have different pooping habits, with some people having a nightly routine and others enjoying a morning bathroom run. But is it normal for one to run to the bathroom after every meal? Not only is it inconvenient but it could be a sign of something going wrong with your body. Have you ever enjoyed a meal and immediately needed to use the restroom?

If so, you might be worried that something is wrong with you. But you don’t need to stress about this! It is actually quite common and doesn't necessarily indicate a health problem.

This phenomenon is called the gastrocolic reflex. When food enters your stomach, it triggers a series of signals in your digestive system. Your stomach stretches to accommodate the food, and sends signals to your brain through the vagus nerve. The brain then communicates with your large intestine, telling it to make room for the new food by moving its current contents along. In other words, you're not pooping out what you just ate, but what has been in your digestive system for a day or two.

What Can Trigger The Gastrocolic Reflex?

When Should You Go See The Doctor?

TV presenter Davina McCall revealed that she had breast cancer, almost a year after she had undergone a surgery to remove her brain tumor. In a video that she posted on her Instagram, she revealed that she was "very angry" when she found out the news, however, she is in a "much more positive place" after she has undergone another surgery three weeks ago to remove the tumor from her breast.

How Did She Realize She Had Breast Cancer?

She said that she found a lump a few weeks ago, however, it came and went back, so she continued to do her work. "I found a lump a few weeks ago. It came and went but then I was working on The Masked Singer and Lorraine, the TV show, and Lorraine Kelly had put signs on the backs of all the doors saying 'check your breasts' and every time I went for a wee, I did that," she said.

She continued: "It was still there, and then one morning I saw myself in the mirror and thought 'I'm going to get that looked at'. I had a biopsy. I found out it was indeed breast cancer and I had it taken out in a lumpectomy nearly three weeks ago."

McCall, who is now 58, says that the lump was "very, very small" and was discovered at an early stage. "I am so relieved to have had it removed and to know that it hasn't spread. My lymph nodes were clear, I didn't have any removed, and all I'm going to do now is have five days of radiotherapy in January as kind of an insurance policy," she said.

"It's been a lot. I was very angry when I found out, but I let go of that, and I feel in a much more positive place now. "I think my message is: get checked if you're worried. Check yourself regularly. If you are due a mammogram, then get it done," she said.

Dense Breast And Mammogram

She also revealed that it was only in August that she got her mammogram done, however, she has dense breasts, and so nothing was detected. "I have dense breasts and I had a mammogram in August, and I was postponing the ultrasound; I just couldn't find time to do it. Don't do that. Get the ultrasound."

Difference Between Breast Ultrasound And A Mammogram

Breast Ultrasound: A breast ultrasound uses sound waves that reflect off the breast tissue to create detailed images of the breast. There is no radiation involved.

Mammogram: A mammogram is an X-ray of the breast. A mammogram is an X-ray of the breast. A diagnostic mammogram focuses more closely on the area(s) of concern. We will get more X-ray views of the concerning area. We perform a diagnostic mammogram any time a patient comes in with symptoms of breast cancer or after an abnormal screening mammogram.

As per the MD Anderson Cancer Center, normal breast tissue and cancerous tissue, both appear white on a mammogram, this is when an ultrasound can help us see small cancers that may be hiding amongst normal breast tissue. This is especially true for women with dense breasts, which means they have more glandular tissue and less fat in their breasts.

However, the MD Anderson Cancer Center mentions that ultrasound is not recommended as a replacement for a mammogram. "Screening mammograms detect about 4 to 6 cases of breast cancer per 1,000 women. When a breast ultrasound is done on top of that, we detect about 2 to 3 more cases. So, breast ultrasound is a valuable screening tool we use in addition to a mammogram," it notes.

Fatigue, joint pain, headaches, and cognitive issues often described as “brain fog” are among the lingering effects many people experience long after recovering from COVID-19. This condition, known as long COVID, can persist for months or even years—and so far, there’s no proven treatment. But researchers are now exploring an unexpected source of hope: a diabetes and obesity drug called tirzepatide.

What Is Tirzepatide?

Tirzepatide is a prescription injectable medication primarily used to manage type 2 diabetes and support chronic weight management in adults who are obese or overweight with a related condition. It is sold under two brand names: Mounjaro, used for diabetes, and Zepbound, approved for weight loss.

Can Weight Loss Drugs Help Long COVID Patients Recover?

In a recent survey led by Dr. Julia Moore Vogel, a program director at Scripps Research, patients with long COVID who were prescribed tirzepatide reported striking results. Between 60% and 90% of participants said their symptoms improved.

“I was expecting only about 30% to show improvement,” Vogel said. “If it’s truly between 60% and 90%, that would be remarkable.”

Encouraged by these early findings, Vogel and her team have launched a clinical trial at Scripps Research to test the drug’s potential benefits more rigorously. The trial, currently a quarter of the way through recruitment, aims to enroll 1,000 participants with long COVID. Half will receive tirzepatide, while the other half will take a placebo.

A Drug with Far-Reaching Effects

Tirzepatide, developed by Eli Lilly, belongs to a class of drugs known as GLP-1 receptor agonists, already popular for their effectiveness in treating obesity and type 2 diabetes. According to Dr. Eric Topol, co-director of the Scripps clinical trial and founder of the Scripps Research Translational Institute, this class of medications could have much broader applications.

“When I say potent, I mean across multiple systems,” Topol explained. “Not just weight loss, but also benefits for the heart, liver, kidneys, migraine headaches, even rheumatoid arthritis and addiction.”

Eli Lilly is supplying the drug for the study, while the project is being funded by the Schmidt Institute for Long COVID (SILC).

A First-of-Its-Kind Virtual Trial

“This is the first long COVID clinical trial that allows patients to participate entirely from home,” Redd said. “Medication is shipped directly to participants, and all assessments are conducted virtually. It opens the door for patients across the U.S. to take part.”

Off-Label Use and Access Challenges

While tirzepatide is already FDA-approved for diabetes and weight loss, its use for long COVID remains experimental. Vogel noted that “off-label” use of approved drugs is common in medicine, but coverage barriers can limit access.

“The challenge for many patients will be insurance,” she explained. “Companies will likely require stronger data before agreeing to cover such an expensive medication.”

A Researcher with Personal Stakes

For Vogel, this research is deeply personal. She has lived with long COVID for five years, an experience that has left her largely homebound, as per KPBS News,

“No treatment I’ve tried has helped,” she shared. “When I saw that 60 to 90 percent of people reported improvement on tirzepatide, I was blown away. I really hope the data confirms it.”

The Scripps team is also studying body-monitor data to track how patients’ symptoms change over time, hoping to gain clearer insights into how and why tirzepatide might work.

Though it’s still early, the findings have offered a glimmer of optimism for millions struggling with the long-term effects of COVID-19. If tirzepatide’s promise holds true, it could mark a significant step toward understanding and treating one of the pandemic’s most stubborn mysteries.

President Donald Trump unveiled a plan to reduce the cost of popular weight loss drugs, including Wegovy and Zepbound, through his self-pay platform, TrumpRx. The move aims to make these medications more accessible to Americans paying out of pocket.

However, drug policy experts warn that the plan may not benefit everyone. Juliette Cubanski, deputy director of the Medicare policy program at KFF, said, “It’s a situation where we have more questions than answers…there’s a lot that the administration itself hasn’t even ironed out as of yet.”

What is TrumpRx?

TrumpRx is a self-pay online platform launched by the Trump administration to sell prescription medications, including popular weight loss drugs, at discounted prices. It is designed for patients who pay out of pocket, aiming to make high-cost treatments like Wegovy and Zepbound more affordable, as per USA Today.

TrumpRx Launches Discounted Weight Loss Medications

President Donald Trump unveiled a plan to reduce the cost of popular weight loss drugs, including Wegovy and Zepbound, through his platform, TrumpRx. The move aims to make these medications more accessible to Americans paying out of pocket.

However, drug policy experts warn that the plan may not benefit everyone. Juliette Cubanski, deputy director of the Medicare policy program at KFF, said, “It’s a situation where we have more questions than answers…there’s a lot that the administration itself hasn’t even ironed out as of yet.”

TrumpRx Zepbound Price Drop: Starting Doses Only

The White House confirmed that the starting doses of GLP-1 pills like Zepbound will cost $149 a month, while injections will have an initial “weighted average” price of $350, expected to drop to $250 within two years.

Experts note this may not reflect real costs. Art Caplan, head of medical ethics at NYU Grossman School of Medicine, explained, as per NBC News, “You can’t really tell from what’s going on…It’s just murky as to how this will take shape, how the programs will work.”

Patients often increase doses over time for effective weight loss, meaning those relying on higher doses may pay significantly more than the starting prices advertised.

TrumpRx and Medicare Coverage: Limited Access

Under the deal, Medicare will pay $245 a month for Zepbound injections, and patients’ copays will be capped at $50. Medicaid enrollees often have no copay.

But Cubanski warns, “Medicare, by law, is barred from covering weight loss drugs alone,” meaning only patients with additional conditions like heart or kidney disease will qualify. Stacie Dusetzina, a health policy professor at Vanderbilt University, said as per NBC News, “Without broader coverage, millions of patients will remain priced out even as the administration touts lower costs.”

TrumpRx: Unapproved Versions Included

The plan also covers drug forms that have not yet received FDA approval, including oral versions and multidose Zepbound pens. Lawrence Gostin, director of the O’Neill Institute at Georgetown University, described this as risky: “It is reckless to negotiate pricing deals on products which the FDA have not yet approved as safe and effective. The administration is getting way out ahead of its own safety agency.”

TrumpRx Savings: Experts Urge Caution

While the deal may seem ambitious, experts caution that actual savings for patients could be limited. Cubanski emphasized, “It just feels a little bit too squishy right now.” Dr Shauna Levy, an obesity specialist, added, “As an obesity community, I think we will remain skeptical of this deal until we see how it actually plays out.”

Limitations in coverage, unapproved drug versions, and higher costs for increased doses mean the impact may be less than anticipated. Patients and healthcare providers will need to carefully navigate these changes, weighing potential savings against practical access and safety considerations.